The Breast Cancer Conference No One Should Miss Kicks Off Thursday

The 39th Miami Breast Cancer Conference, to be presented in hybrid form, kicks off later this week in Miami Beach, Florida, and virtually around the world. The Conference opens Thursday, March 3, and runs through Sunday, March 6, 2022.

Renowned for delivering practical education that clinicians can readily adopt in their practices and with their patients, the Conference this year will once again bring together world-class experts in surgical, medical, and radiation oncology, as well as geneticists, pathologists, radiologists, and supportive care specialists.

Patrick I. Borgen, MD, Chair of the Department of Surgery at Maimonides Medical Center, Brooklyn, NY, is Chairman of this year’s Conference, and a fervent advocate for its value:

“I come back every year from Miami with a whole new set of ideas, a whole new set of questions, and I think a far better approach to my patients,” Dr. Borgen said. “Miami allows us to look at breast cancer from every direction and really put together a plan that is best for our patients. This is absolutely a meeting that will change your practice.”

A Conference attendee himself for more than 25 years, Dr. Borgen took a minute to provide an overview for the benefit of those attending for the first time:

“First-time attendees should know that ours is a world-class faculty hand chosen over the previous year, presenting their knowledge and information in a truly world-class conference facility. Also, we employ an ultra -short format. No lecture is more than 15 minutes. Also, our speakers begin with their concluding slide, telling us “This is what I do in my practice and why.” It is intensely practical.”

Topics that the Conference will examine include management of patients with HER2 positive breast cancer in both the early and metastatic settings, checkpoint inhibitors, t cell modulators, PARP inhibitors, and more. From a surgical perspective, topics will include advances like reverse axillary mapping and de-escalation of surgery in the axilla.

“One theme we will highlight is a continued exploration of the de-escalation of care for breast cancer,” Dr. Borgen said. “We’ll talk about things like circulating tumor cells and how they might replace complete pathologic response in our patients. And of course, we will have our debates of controversial issues.”

ConferenceInsider™, in association with Professional Edition, will be covering several sessions, including the following:

  • Aligning Data With Strategy to Improve Breast Cancer Outcomes With PARP, HER2/3, and TROP 2
  • Incorporating Immunotherapy into the Treatment of Early-Stage Breast Cancer
  • Emerging Data on Oral Selective Estrogen Receptor Degraders and Other Novel Hormonal Therapies
  • Molecular Imaging for Staging and Following Breast Cancer
  • How COVID-19 Killed Evidence-Based Medicine
  • Universal Hereditary Testing in Breast Cancer
  • Balancing De-Escalation Across Modes of Therapy
  • How to Get Involved in Clinical Research . . . and Recognize What Research Is Worthwhile

Attendees own cases often support the presentations and conversations at the Conference. This year’s sessions will include discussion of the following cases:

  • Male With Recently Discovered Non-BRCA1/2 Pathogenic Variant
  • Patient With Clinically Node-Positive ER+, HER2 Invasive Lobular Carcinoma and Low Genomic Risk Score
  • Premenopausal Patient With Low 21-Gene Recurrence Score
  • Patient With BRCA-Mutated Early State Triple-Negative Breast Cancer
  • Patient With HER2+ Central Nervous System Metastasis
  • Patient With High-Risk Early-Stage HR+ Breast Cancer

“This is an information dense meeting,” said Dr. Borgen. “You will learn a tremendous amount across the four days.”

The Conference opens at 11:00 am EST on Thursday.